ReviewCureus2025
Critical Appraisal of Evidence on Platelet-Rich Plasma and Stem Cell Therapy for Stress Urinary Incontinence: A Narrative Review.
Review in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed, 1 synthesis or guideline pooled it.
- Autologous regenerative cell therapy for female stress urinary incontinence: a systematic review and meta-analysis of clinical outcomes.Frontiers in medicine · 2026Pooled it
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Stress urinary incontinence (SUI) is a common condition, affecting 20% of individuals. It is defined by the involuntary loss of urine during activities that increase intra-abdominal pressure, such as coughing or physical exertion. SUI may result from urethral hypermobility or intrinsic sphincter deficiency. Conventional treatments, including pelvic floor exercises, sling surgeries, and bulking agents, have varying success rates and complications. Emerging regenerative therapies such as platelet-rich plasma (PRP) and stem cell therapy (SCT) hold promise for improving urethral support and rhabdosphincter function. This review critically examines recent evidence on the efficacy and safety of PRP and SCT for treating SUI. A thorough search of databases was conducted, focusing on clinical studies published on adult SUI patients treated with PRP and SCT interventions. Nine clinical trials met the inclusion criteria. All studies were conducted between 2011 and 2024. The keywords used were "Stress Urinary Incontinence", "Regenerative Medicine", Cell- and Tissue-Based Therapy", "Stem Cell Transplantation", and "Stem Cell". These studies investigated the use of PRP and mesenchymal stem cells, but inconsistencies in treatment protocols raise concerns about the reliability and generalizability of their findings. Additionally, there was a lack of detailed assessment tools to evaluate sphincter regeneration post-treatment and no standardized methods for PRP preparation. This review describes the current status of stem cell research on SUI and suggests future directions to facilitate clinical applications. Future trials should follow a standardized protocol that includes detailed methods for stem cell or PRP preparation, dosage determination, application techniques, and necessary pre-procedural assessments. Objective outcome measures must incorporate improvements in urodynamic parameters, MRI evidence of sphincter regeneration, and comprehensive long-term follow-up evaluations. This approach ensures consistency and reliability in assessing treatment efficacy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.